Cargando…

Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke

BACKGROUND AND PURPOSE—: It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional outcomes, technical aspects, and complications of EVT between patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Compagne, Kars C.J., van der Sluijs, Pieter M., van den Wijngaard, Ido R., Roozenbeek, Bob, Mulder, Maxim J.H.L., van Zwam, Wim H., Emmer, Bart J., Majoie, Charles B.L.M., Yoo, Albert J., Lycklama à Nijeholt, Geert J., Lingsma, Hester F., Dippel, Diederik W.J., van der Lugt, Aad, van Es, Adriaan C.G.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358188/
https://www.ncbi.nlm.nih.gov/pubmed/31287757
http://dx.doi.org/10.1161/STROKEAHA.118.023117
_version_ 1783391966458806272
author Compagne, Kars C.J.
van der Sluijs, Pieter M.
van den Wijngaard, Ido R.
Roozenbeek, Bob
Mulder, Maxim J.H.L.
van Zwam, Wim H.
Emmer, Bart J.
Majoie, Charles B.L.M.
Yoo, Albert J.
Lycklama à Nijeholt, Geert J.
Lingsma, Hester F.
Dippel, Diederik W.J.
van der Lugt, Aad
van Es, Adriaan C.G.M.
author_facet Compagne, Kars C.J.
van der Sluijs, Pieter M.
van den Wijngaard, Ido R.
Roozenbeek, Bob
Mulder, Maxim J.H.L.
van Zwam, Wim H.
Emmer, Bart J.
Majoie, Charles B.L.M.
Yoo, Albert J.
Lycklama à Nijeholt, Geert J.
Lingsma, Hester F.
Dippel, Diederik W.J.
van der Lugt, Aad
van Es, Adriaan C.G.M.
author_sort Compagne, Kars C.J.
collection PubMed
description BACKGROUND AND PURPOSE—: It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional outcomes, technical aspects, and complications of EVT between patients with acute ischemic stroke because of M2 and M1 occlusions in clinical practice. Furthermore, outcome and complications after EVT in dominant and nondominant caliber M2 division occlusions were studied. METHODS—: Data were obtained from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) which is an ongoing observational study in 16 Dutch centers performing EVT in the Netherlands. Functional outcome was measured with the modified Rankin Scale score at 90 days. Neurological recovery (delta National Institutes of Health Stroke Scale), successful reperfusion rates (extended Thrombolysis in Cerebral Infarction ≥2B), and safety outcomes were also investigated. Associations between occlusion location and outcome were analyzed with ordinal logistic regression models, with adjustment for other prognostic factors. RESULTS—: In total, 244 (24%) patients with an M2 and 759 (76%) patients with an M1 occlusion who underwent EVT were analyzed. Functional outcomes were not significantly different between patients with M2 versus M1 occlusions (adjusted common odds ratio, 1.24; 95% CI, 0.87–1.73). Occurrence of symptomatic intracerebral hemorrhage was also similar for M2 and M1 occlusions (6.6% versus 5.9%; P=0.84). Further analysis about dominance of an M2 branch was performed in 175 (72%) patients. Neurological recovery was comparable (mean delta National Institutes of Health Stroke Scale, −2±10 for dominant M2, −5±5 for nondominant M2, and −4±9 [P=0.24] for M1 occlusions). Furthermore, the effect of reperfusion status on functional outcome was comparable between occlusion divisions (common odds ratio, 1.27; 95% CI, 1.06–1.53 for dominant M2; common odds ratio, 1.32; 95% CI, 0.93–1.87 for nondominant M2; and common odds ratio, 1.35; 95% CI, 1.24–1.46 for M1 occlusions). CONCLUSIONS—: Outcomes and complication rates after EVT were similar in patients with M2 and M1 occlusions. Although based on observational data and a limited sample size, a similar association of reperfusion status with functional outcome for all subgroups provides no evidence that patients with either a dominant or a nondominant M2 occlusion should be routinely excluded from EVT.
format Online
Article
Text
id pubmed-6358188
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-63581882019-02-20 Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke Compagne, Kars C.J. van der Sluijs, Pieter M. van den Wijngaard, Ido R. Roozenbeek, Bob Mulder, Maxim J.H.L. van Zwam, Wim H. Emmer, Bart J. Majoie, Charles B.L.M. Yoo, Albert J. Lycklama à Nijeholt, Geert J. Lingsma, Hester F. Dippel, Diederik W.J. van der Lugt, Aad van Es, Adriaan C.G.M. Stroke Original Contributions BACKGROUND AND PURPOSE—: It is unclear whether endovascular treatment (EVT) is beneficial for patients with acute ischemic stroke with occlusion of the M2 segment of the middle cerebral artery. We aimed to compare functional outcomes, technical aspects, and complications of EVT between patients with acute ischemic stroke because of M2 and M1 occlusions in clinical practice. Furthermore, outcome and complications after EVT in dominant and nondominant caliber M2 division occlusions were studied. METHODS—: Data were obtained from the MR CLEAN Registry (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) which is an ongoing observational study in 16 Dutch centers performing EVT in the Netherlands. Functional outcome was measured with the modified Rankin Scale score at 90 days. Neurological recovery (delta National Institutes of Health Stroke Scale), successful reperfusion rates (extended Thrombolysis in Cerebral Infarction ≥2B), and safety outcomes were also investigated. Associations between occlusion location and outcome were analyzed with ordinal logistic regression models, with adjustment for other prognostic factors. RESULTS—: In total, 244 (24%) patients with an M2 and 759 (76%) patients with an M1 occlusion who underwent EVT were analyzed. Functional outcomes were not significantly different between patients with M2 versus M1 occlusions (adjusted common odds ratio, 1.24; 95% CI, 0.87–1.73). Occurrence of symptomatic intracerebral hemorrhage was also similar for M2 and M1 occlusions (6.6% versus 5.9%; P=0.84). Further analysis about dominance of an M2 branch was performed in 175 (72%) patients. Neurological recovery was comparable (mean delta National Institutes of Health Stroke Scale, −2±10 for dominant M2, −5±5 for nondominant M2, and −4±9 [P=0.24] for M1 occlusions). Furthermore, the effect of reperfusion status on functional outcome was comparable between occlusion divisions (common odds ratio, 1.27; 95% CI, 1.06–1.53 for dominant M2; common odds ratio, 1.32; 95% CI, 0.93–1.87 for nondominant M2; and common odds ratio, 1.35; 95% CI, 1.24–1.46 for M1 occlusions). CONCLUSIONS—: Outcomes and complication rates after EVT were similar in patients with M2 and M1 occlusions. Although based on observational data and a limited sample size, a similar association of reperfusion status with functional outcome for all subgroups provides no evidence that patients with either a dominant or a nondominant M2 occlusion should be routinely excluded from EVT. Lippincott Williams & Wilkins 2019-02 2019-01-21 /pmc/articles/PMC6358188/ /pubmed/31287757 http://dx.doi.org/10.1161/STROKEAHA.118.023117 Text en © 2019 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
spellingShingle Original Contributions
Compagne, Kars C.J.
van der Sluijs, Pieter M.
van den Wijngaard, Ido R.
Roozenbeek, Bob
Mulder, Maxim J.H.L.
van Zwam, Wim H.
Emmer, Bart J.
Majoie, Charles B.L.M.
Yoo, Albert J.
Lycklama à Nijeholt, Geert J.
Lingsma, Hester F.
Dippel, Diederik W.J.
van der Lugt, Aad
van Es, Adriaan C.G.M.
Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
title Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
title_full Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
title_fullStr Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
title_full_unstemmed Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
title_short Endovascular Treatment: The Role of Dominant Caliber M2 Segment Occlusion in Ischemic Stroke
title_sort endovascular treatment: the role of dominant caliber m2 segment occlusion in ischemic stroke
topic Original Contributions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358188/
https://www.ncbi.nlm.nih.gov/pubmed/31287757
http://dx.doi.org/10.1161/STROKEAHA.118.023117
work_keys_str_mv AT compagnekarscj endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT vandersluijspieterm endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT vandenwijngaardidor endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT roozenbeekbob endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT muldermaximjhl endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT vanzwamwimh endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT emmerbartj endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT majoiecharlesblm endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT yooalbertj endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT lycklamaanijeholtgeertj endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT lingsmahesterf endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT dippeldiederikwj endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT vanderlugtaad endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke
AT vanesadriaancgm endovasculartreatmenttheroleofdominantcaliberm2segmentocclusioninischemicstroke